Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531384 | 0.94 | EGFR (0.46) | EGFRIGF1RCHUKINSRMAPK8 | |
| SCHEMBL2994829 | 0.91 | IGF1R (0.37) | EGFRIGF1RCHUKINSRMAPK8 | |
| Trifluoroacetic Acid SCHEMBL2991605 | 0.88 | IGF1R (0.38) | EGFRIGF1RCHUKINSRMAPK8 | |
| Trifluoroacetic Acid SCHEMBL2984502 | 0.85 | IGF1R (0.40) | IGF1RCHUKINSRMAPK8CAMKK2 | |
| Trifluoroacetic Acid SCHEMBL2984463 | 0.85 | IGF1R (0.40) | IGF1RCCNT1CDK9 | |
| SCHEMBL2991608 | 0.84 | IGF1R (0.37) | EGFRIGF1RCHUKINSRMAPK8 | |
| SCHEMBL5531332 | 0.82 | IGF1R (0.42) | IGF1RCHUKINSRMAPK8CAMKK2 | |
| SCHEMBL5531129 | 0.81 | IGF1R (0.42) | EGFRIGF1R | |
| SCHEMBL2985996 | 0.80 | IGF1R (0.48) | EGFRIGF1RCHUKINSRMAPK8 | |
| SCHEMBL2984504 | 0.80 | IGF1R (0.39) | IGF1RCHUKINSRMAPK8CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | EGFR 560/4885IGF1R 606/4885CHUK 316/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | EGFR 560/4885IGF1R 606/4885CHUK 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.